Rigel and Medison Announce Health Canada Approval of TAVALISSE(R), an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
SOUTH SAN FRANCISCO, Calif. and PETACH TIKVA, Israel, Nov. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Medison Pharma (Medison) today announced that Health Canada has approved the new drug submissio... Biopharmaceuticals, Regulatory Rigel Pharmaceuticals, Medison Pharma, TAVALISSE, fostamatinib, thrombocytopenia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Canada Health | Israel Health | Marketing | Middle East Health | Pharmaceuticals | Thrombocytopenia